Journal of Clinical Anesthesia
Volume 21, Issue 7 , Pages 502-507 , November 2009

Aprotinin use during cardiac surgery: recent alterations and effects on blood product utilization

  • Zaneta Y. Strouch, MD, MPH (Fellow)

      Affiliations

    • Department of Anesthesia and Critical Care, University of Chicago Medical Center, Chicago, IL 60637, USA
    • ,
  • Melinda L. Drum, PhD (Assistant Professor, Research Associate)

      Affiliations

    • Department of Health Studies, University of Chicago Medical Center, Chicago, MC 4028, IL 60637, USA
    • ,
  • Mark A. Chaney, MD (Associate Professor, Director)

      Affiliations

    • Department of Anesthesia and Critical Care, University of Chicago Medical Center, Chicago, IL 60637, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 773 702 5951; fax: +1 773 834 3920.

Received 20 May 2008 ,Revised 2 December 2008 ,Accepted 4 December 2008.

References 

  1. McEvoy MD, Reeves ST, Reves JG, Spinale FG. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg. 2007;105:949–962
  2. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442–448
  3. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery; meta-analysis using perioperative blood transfusion as the outcome. Anesth Analg. 1997;85:1258–1267
  4. Mangano DT, Tudor IC, Dietzel C Multicenter Study of Perioperative Ischemia Research Group. Ischemic Research and Education Foundation: the risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353–365
  5. Mangano DT, Miao Y, Vuylsteke A Multicenter Study of Perioperative Ischemia Research Group. Ischemia Research and Education Foundation: mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297:471–479
  6. Hill SE. Pro: Aprotinin should be used in coronary artery bypass graft surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2007;21:298–301
  7. Augoustides J. Con: Aprotinin should not be used in cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2007;21:302–304
  8. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319–2331
  9. Koch CG, Khandwala F, Li L, et al. Persistent effect of red cell transfusion on health-related quality of life after cardiac surgery. Ann Thorac Surg. 2006;82:13–20
  10. Brown JR, Birkmeyer NJO, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801–2813
  11. Bridges CR. Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation. 2007;115:2790–2792
  12. Warren O, Mandal K, Hadjianastassiou MD, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007;83:707–714
  13. Surgenor SD, DeFoe GR, Fillinger MP, et al. Intraoperative red blood cell transfusion during coronary artery bypass graft surgery increases the risk of postoperative low-output heart failure. Circulation. 2006;114(1 Suppl):143–148
  14. Rana R, Fernandez-Perez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46:1478–1483
  15. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;131:1308–1314

PII: S0952-8180(09)00259-1

doi: 10.1016/j.jclinane.2008.12.021

Journal of Clinical Anesthesia
Volume 21, Issue 7 , Pages 502-507 , November 2009

Article Tools

* Image Usage & Resolution